BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) went up by 7.17% from its latest closing price compared to the recent 1-year high of $19.99. The company’s stock price has collected 9.35% of gains in the last five trading sessions. Barron’s reported on 09/27/21 that Medicine’s Golden Age Is Dawning. 10 Stocks to Play the Latest Innovations.
Is It Worth Investing in BioCryst Pharmaceuticals Inc. (NASDAQ :BCRX) Right Now?
Plus, the 36-month beta value for BCRX is at 2.30. Opinions of the stock are interesting as 8 analysts out of 13 who provided ratings for BioCryst Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 5 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $17.08, which is $7.28 above the current price. BCRX currently public float of 183.87M and currently shorts hold a 16.07% ratio of that float. Today, the average trading volume of BCRX was 4.75M shares.
BCRX’s Market Performance
BCRX stocks went up by 9.35% for the week, with a monthly jump of 14.27% and a quarterly performance of -38.03%, while its annual performance rate touched -40.14%. The volatility ratio for the week stands at 7.36% while the volatility levels for the past 30 days are set at 6.36% for BioCryst Pharmaceuticals Inc. The simple moving average for the period of the last 20 days is 5.12% for BCRX stocks with a simple moving average of -24.38% for the last 200 days.
Analysts’ Opinion of BCRX
Many brokerage firms have already submitted their reports for BCRX stocks, with Barclays repeating the rating for BCRX by listing it as a “Equal Weight.” The predicted price for BCRX in the upcoming period, according to Barclays is $13 based on the research report published on April 18th of the current year 2022.
BofA Securities, on the other hand, stated in their research note that they expect to see BCRX reach a price target of $14, previously predicting the price at $21. The rating they have provided for BCRX stocks is “Neutral” according to the report published on April 11th, 2022.
Oppenheimer gave a rating of “Outperform” to BCRX, setting the target price at $16 in the report published on December 10th of the previous year.
BCRX Trading at 5.75% from the 50-Day Moving Average
After a stumble in the market that brought BCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.12% of loss for the given period.
Volatility was left at 6.36%, however, over the last 30 days, the volatility rate increased by 7.36%, as shares surge +18.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.53% lower at present.
During the last 5 trading sessions, BCRX rose by +9.35%, which changed the moving average for the period of 200-days by -32.65% in comparison to the 20-day moving average, which settled at $9.75. In addition, BioCryst Pharmaceuticals Inc. saw -26.57% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at BCRX starting from ABERCROMBIE GEORGE B, who sale 5,000 shares at the price of $11.04 back on Apr 18. After this action, ABERCROMBIE GEORGE B now owns 0 shares of BioCryst Pharmaceuticals Inc., valued at $55,200 using the latest closing price.
Thackray Helen M., the Chief R&D Officer of BioCryst Pharmaceuticals Inc., sale 7,600 shares at $16.20 during a trade that took place back on Apr 01, which means that Thackray Helen M. is holding 136,400 shares at $123,120 based on the most recent closing price.
Stock Fundamentals for BCRX
Current profitability levels for the company are sitting at:
- -113.08 for the present operating margin
- +94.88 for the gross margin
The net margin for BioCryst Pharmaceuticals Inc. stands at -117.11. Equity return is now at value 148.00, with -46.80 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 5.46.